Evidence map›Paper›PMID 31531539›Full record

ArticleActa cirurgica brasileira2019

Short-term use of resveratrol in alloplastic graft material applied with calvarial bone defects in rats.

Nihat Laçin, Engin Deveci

Open access · goldAbstract read
In one paragraph

Article in Acta cirurgica brasileira, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Nihat LaçinPhD, Assistant Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Katip Çelebi, İzmir, Turkey. Technical procedures, manuscript preparation and writing, final approval.ORCID http://orcid.org/0000-0003-3661-2378
Engin DeveciPhD, Professor, Department of Histology and Embryology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. Technical procedures, histopathological examinations, manuscript preparation and writing, final approval.ORCID http://orcid.org/0000-0001-5493-7083
Dicle University · TRIzmir Kâtip Çelebi University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe effects of resveratrol administration on calvarial bone defects with alloplastic graft material was investigated for osteoinductive reaction and bone development in rats.

methodsHealthy male rats were randomly divided into 3 groups consisting of 10 rats. Groups were as follows: control (defect) group, defect + graft group, and defect + graft + resveratrol group. A calvarial bone defect was created in all groups, alloplastic bone grafts were applied to the defect in the 2nd and 3rd group, resveratrol (5 mg/kg/day) was added to the drinking water of the animals following graft application for 28 days in the 3rd group.

resultsIncrease in osteoclasts and necrotic changes were observed histopathologically in the control group. In the 2nd group, reduction of inflammation, congestion of blood vessels, increased osteblastic activity, osteoinductive effect, progression of osteocyte development and increased collagen fibers in connective tissue were observed. In the 3rd group, osteoblasts seemed to secrete bone matrix and accelerate osteoinductive effect with increased osteopregenitor activity and positive osteopontin and osteonectin expressions.

conclusionResveratrol treatment was thought to be an alternative and supportive drug for implant application by inducing new bone formation in the calvaral defect region as a result of short-term treatment.

Indexed as

AnimalsBone RegenerationBone SubstitutesBone TransplantationDisease Models, AnimalDrug Administration ScheduleMaleOsseointegrationOsteoblastsOsteogenesisOsteonectinOsteopontinRatsResveratrolSkullBone SubstitutesOsteonectinOsteopontinResveratrol

Identifiers

PMID31531539
PMCPMC6746564
OpenAlexW2972965244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.